ArticleCureus2025
Past Marks: A Case Report of Basal Cell Carcinoma Induced by Arsenic Exposure.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Basal cell carcinoma (BCC) is one of the most common forms of skin cancer worldwide. Chronic exposure to arsenic, particularly in its inorganic form, has been identified as a potential etiological factor in its development. However, not all individuals exposed to arsenic will develop BCC, suggesting that genetic and environmental factors influence susceptibility. Arsenic was historically used for medicinal purposes, most notably in Fowler's solution, once prescribed for conditions such as psoriasis. Despite its past therapeutic applications, arsenic is now classified as a carcinogen due to its well-established toxicity. The authors present a case of a 69-year-old patient with a history of prolonged use of Fowler's solution for psoriasis, who subsequently developed recurrent BCC, requiring continuous surveillance and treatment, such as surgery, cryotherapy, and laser therapy. Given the significant personal history of long-term exposure to an arsenic-based solution, arsenic was identified as the most plausible contributing factor in the development of cutaneous neoplasms in this case. This case highlights the importance of a detailed medical history, including drugs or other toxic agents that the patient may have used previously. In particular, patients with known exposure to arsenic, especially for periods exceeding six months, should undergo lifelong surveillance due to the increased risk of developing skin cancer and other arsenic-related health conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.